COVID-19 Funding Opportunities

1. National Institutes of Health (NIH)

**Notice of Special Interest (NOSI): Emergency Competitive Revisions for Social, Ethical, and Behavioral Implications (SEBI) Research on COVID-19 Testing among Underserved and/or Vulnerable Populations**

This Notice of Special Interest (NOSI) highlights the urgent need to understand the social, ethical, and behavioral implications (SEBI) of COVID-19 testing among underserved and/or vulnerable populations across the United States through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

**Deadline: September 8, 2020**

**Notice of Special Interest (NOSI): Emergency Competitive Revisions for Community-Engaged Research on COVID-19 Testing among Underserved and/or Vulnerable Populations**

This Notice of Special Interest (NOSI) highlights the urgent need to understand and address COVID-19 morbidity and mortality disparities among underserved and vulnerable populations across the United States. These two-year community-engaged Testing Research Projects will examine SARS-CoV-2 infection patterns and efforts to increase access and effectiveness of diagnostic methods through the Rapid Acceleration of Diagnostics for Underserved Populations (RADx-UP) initiative. The overarching goal is to understand factors that have led to disproportionate burden of the pandemic on these underserved populations so that interventions can be implemented to decrease these disparities. The funding for this supplement program is provided from the Paycheck Protection Program and Health Care Enhancement Act, 2020.

**Deadline: September 8, 2020**

**Emergency Awards: RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) (U01 - Clinical Trials Not Allowed)**

This emergency FOA provides an expedited funding mechanism as part of the Rapid Acceleration of Diagnostics-Radical (RADx-rad) initiative. As one of the programs within the NIH Rapid Acceleration of Diagnostics-Radical (RADx-rad) program the RADx-rad Wastewater Detection of SARS-COV-2 (COVID-19) FOA will support wastewater-based testing (WBT) surveillance which can provide detailed mapping of the extent and spread of COVID-19. Wastewater testing has been shown to be orders of magnitude cheaper and faster than clinical screening, albeit serving as a complementary approach rather than substituting individual-level testing and screening. The purpose of this FOA is to solicit cooperative agreements both for field studies and for small business research and development projects in the field of WBT, to address topics such as: investigation and demonstration of specific approaches aiming to increase sensitivity and to inform and optimize sample collection; implementation and development of optimized approaches to extrapolate estimation of population-level data within the community; development of optimized intervention strategies, and incorporation of computational, statistical, and mathematical models.

**Deadline: September 15, 2020**

**National Heart, Lung, Blood Institute (NHLBI)**

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19). NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

**Deadline: Rolling, through October 5, 2020**
COVID-19 Funding Opportunities

**Community Interventions to Address the Consequences of the COVID-19 Pandemic among Health Disparity and Vulnerable Populations (R01 - Clinical Trial Optional)**
This Funding Opportunity Announcement (FOA) encourages applications to implement and evaluate community interventions testing 1) the impacts of mitigation strategies to prevent COVID-19 transmission in NIH-designated health disparity populations and other vulnerable groups; and 2) already implemented, new, or adapted interventions to address the adverse psychosocial, behavioral, and socioeconomic consequences of the pandemic on the health of these groups.
**Deadline: December 1, 2020**

**Digital Healthcare Interventions to Address the Secondary Health Effects Related to Social, Behavioral, and Economic Impact of COVID-19 (R01 - Clinical Trial Optional)**
This FOA aims to support research to strengthen the healthcare response to Coronavirus Disease 2019 (COVID-19) caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and future public health emergencies, including pandemics. The purpose of this funding opportunity is to focus on the role and impact of digital health interventions to address access, reach, delivery, effectiveness, scalability and sustainability of health assessments and interventions for secondary effects that are utilized during and following the pandemic, particularly in populations who experience health disparities and vulnerable populations.
**Deadline: December 2, 2020; March 2, 2021**

**National Institute of General Medical Sciences (NIGMS)**
Predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants). Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection; rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR grants only).
**Deadline: Rolling through February 6, 2021**

**National Institute of Allergy and Infectious Diseases (NIAID)**
NOSI: Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). Topics include: Viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.
**Deadline: Rolling, through March 25, 2021**

**National Institute of Drug Abuse (NIDA)**
Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus. NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.
**Deadline: Rolling, through March 31, 2021**

**National Institute of Allergy and Infectious Diseases (NIAID) - Emergency Awards: Rapid Investigation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)**
The purpose of this Funding Opportunity Announcement (FOA) is to provide an expedited funding mechanism for research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19). NIAID is issuing this FOA in response to the declared public health emergency issued by the Secretary, HHS, for 2019 Novel Coronavirus (COVID-19).
**Deadline: Rolling, through April 30, 2021**
II. National Science Foundation (NSF)

Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19

NSF is seeking Phase I SBIR/STTR proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis.

**Deadline: December 3, 2020**

III. U.S. Department of Agriculture (USDA)

**National Institute of Food and Agriculture (NIFA) Agriculture and Food Research Initiative (AFRI)**

In response to the current need for more COVID-19 information, certain NIFA programs will allow submission of COVID-19 relevant projects outside of their normal deadlines. Focus areas of interest include, but are not limited to the following:

1. Animal Nutrition, Growth and Lactation (A1231),
2. Critical Agricultural Research and Extension (CARE) (A1701),
3. Diseases of Agricultural Animals (A1221),
4. Food Safety and Defense (A1332),
5. Foundational Knowledge of Plant Products (A1103)
6. Economics, Markets, and Trade (A1641)

**Deadline: Varies by program**

IV. Other US Funding Agencies

**Biomedical Advanced Research and Development Authority (BARDA)**

BARDA has updated its Broad Agency Announcements (BAAs) to focus exclusively on addressing the COVID-19 threat. BARDA, with a total budget of $512 Million, is seeking proposals for projects related to products to diagnose, prevent or treat novel coronavirus infections

**Deadline: Rolling, through 10/31/2020**

**Fast Grants**

Fast grants are available exclusively to PIs at academic institutions already working on COVID-19 related projects that could help with the pandemic within the next six months.

**Due Date: Rolling, award decisions made in 48 hours**

**Ohio Department of Agriculture – Coronavirus Relief Fund: Local Fair Economic Support**

Governor DeWine, Lt. Gov. Husted, House Speaker Householder, and Senate President Obhof have established that it is necessary to provide Coronavirus Relief Funding to County and Independent Fairs in Ohio to ensure that fairs are conducted in a safe manner, consistent with good health practices necessitated by COVID-19. The leaders of Ohio government have determined that the level of necessary funding is $50,000 for each fair that conducts a junior fair during calendar year 2020 and $15,000 for each fair that does not conduct a junior fair during calendar year 2020.

**Deadline: Not Specified**

**Wellcome, Bill & Melinda Gates Foundation, and Mastercard**

The Bill & Melinda Gates Foundation, Wellcome, and Mastercard have committed up to $125 million in seed funding to speed-up the response to the COVID-19 epidemic by identifying, assessing, developing, and scaling-up treatments. The Accelerator is seeking partners for the following activities:

- Identifying candidate compounds by testing approved drugs for activity against COVID-19, screening libraries of compounds with confirmed safety data, and considering new investigational compounds and monoclonal antibodies.
- Developing drugs or monoclonal antibodies that pass initial screening.
- Scaling up production and commercialization of successful drugs and monoclonal antibodies.

**Deadline: Not Specified**